Om du vill rapportera en biverkning gällande en av Lillys produkter, kontakta oss via e-post på DK_PHv@lilly.com eller på telefon +45 4526 6040. Har du ytterligare medicinska frågor gällande en av Lillys produkter, kontakta oss via länken ovan.
Cyramza ® (ramucirumab)
Denna information är endast avsedd för sjukvårdspersonal verksam i Sverige och som svar på din fråga. Informationen nedan är på engelska
The REVEL trial was a phase 3, multicenter, randomized, double-blind, placebo-controlled trial in patients with pathologically confirmed, squamous or nonsquamous, stage IV NSCLC with disease progression during or after 1 prior platinum-based chemotherapy. Prior treatment with bevacizumab and prior maintenance therapy were allowed and all patients had an ECOG PS of 0 or 1. Patients were randomly assigned in a 1:1 ratio (stratified by sex, region, PS, and previous maintenance therapy) to receive treatment with ramucirumab (10 mg/kg every 3 weeks) plus docetaxel (75 mg/m2 every 3 weeks) (n=628) or placebo plus docetaxel (75 mg/m2 every 3 weeks) (n=625) until disease progression, unacceptable toxicity, withdrawal, or death.1
Prior TKI Therapy
Patients were excluded from participation in the REVEL study if their only prior treatment for advanced disease was a TKI (eg, erlotinib).1 The number of patients who received prior TKI therapy in addition to one prior platinum-based chemotherapy regimen in the REVEL study is presented in Table 1
Table 1. Prior TKI Therapy in the REVEL Study2
Prior Systemic Therapy |
Ramucirumab
+ Docetaxel |
Placebo
+ Docetaxel |
Any TKI inhibitor |
23 |
25 |
Erlotinib |
19 |
11 |
Gefitinib |
3 |
10 |
Abbreviation: TKI = tyrosine kinase inhibitor.
1. Garon EB, Ciuleanu TE, Arrieta O, et al. Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial. Lancet. 2014;384(9944):665-673. http://dx.doi.org/10.1016/S0140-6736(14)60845-X
2. Data on file, Eli Lilly and Company and/or one of its subsidiaries.
Glossary
ECOG = Eastern Cooperative Oncology Group
NSCLC = non-small cell lung cancer
PS = performance status
TKI = tyrosine kinase inhibitor
Datum fӧr senaste ӧversyn 2019 M11 20